First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials.
Thierry LandreJean-Baptiste AssiéKader ChouahniaGaetan Des GuetzJean-Bernard AuliacChristos ChouaidPublished in: Expert review of anticancer therapy (2024)
PROSPERO CRD42024508055.